

TEGO™ Connector

Never Before in Dialysis...A Closed System for Central Venous Catheters



Lower your costs

Protect the catheter from contamination

Flow rates of greater than 600cc/min

Ultra small and comfortable for the patient with
the first non-abrasive exterior

COST SAVINGS

A microbiologically and mechanically closed connector:


Ten percent (10%) of patients with a long term central venous catheter for chronic hemodialysis will develop a blood stream infection (CRBSI)¹⁻⁸. By use of the microbiologically closed Tego Connector health care workers can reduce the risk of CRBSI resulting from repeat exposure, or 'opening' and manipulation of the catheter hub.¹⁵ The Tego has been validated for functional and microbiological efficacy for up to seven days.¹⁸



PERFORMANCE

Flow rates greater than 600mL/min:

The Tego Connector remains in place during the hemodialysis treatment. It permits flow rates through an unobstructed fluid path of greater than 600mL/min.¹⁰



CATHETER PATENCY

Infinite Positive Pressure:

Twenty-five percent (25%) of long term central venous catheters used in Hemodialysis develop thrombotic occlusions.¹¹⁻¹³ The Tego provides an automatic positive displacement of fluid at the end of each catheter flush. This positive pressure prevents the reflux of blood into the catheter lumen which may lead to thrombotic occlusion.¹⁶⁻¹⁷



TEGO™ Connector

How does it work?

The Tego Connector creates a mechanically and microbiologically closed system when attached to the hub of a catheter. It will prevent the ingress of micro-organisms by maintaining a seal while attaching or removing blood lines, flush syringes and when it is not being accessed at all. Simply disinfect the Tego by swabbing before each access and the sterility of the fluid path will NOT be compromised!

REFERENCES

1. Gessaroli G, Galli F, Mandolfo S. Accessi Vascolari Per Emodialisi. 2001 Edition, 1-34.
2. Powe NR, Jaar B, Furth SL. Septicemia in Diálysis Patients: Incidence, Risk Factors, and Prognosis. *Kidney Int* 1999; 5, 1081-1090.
3. Nielsen, J, Ladefoged SD, Kolmos HJ. Dialysis Catheter-Related Septicaemia. Focus on Staphylococcus Aureus Septicaemia. *Nephr Dial Transplant* 1998; 13: 2847.
4. Marr KA, Sexton DJ, Conlon PJ, et al. Cathéter-Related Bacteremia and Outcome of Attempted Salvage in Patients Undergoing Hemodiállysis. *Ann Inter Med* 1997; 12, 275-280.
5. Dittmer ID, Sharp D, Mc Nulthy C, et al. A Prospective Study of Central Venous Hemodialysis Catheter Colonization and Peripheral Bacteremia. *Clin Nephrol* 1999; 51: 34-39.
6. Beathard G. Management of Bacteremia Associated with Tunneled-Cuffed Hemodialysis Catheters. *J Am Soc Nephrol* 1999; 10: 1045.
7. Canaud B. Hemodialysis Catheter-Related Infection: Time for Action. *Nephrol Dial Transplant* 1999; 14: 2288-90.
8. Saad TF. Bacteremia Associated with Tunneled, Cuffed Hemodialysis Catheter. *Am J Kidney Dis* 1999; 34: 114-24.
9. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased Resource Use Associated with Catheter-Related Bloodstream Infection in the Surgical Intensive Care Unit. *Arch Surg* 2001; 136. 229-234.
10. Test Report 04-135: Positive Pressure Flow, Flow Rate vs Pressure and Vacuum Decay Flow Rate Report. May 26, 2004. Study on file; ICU Medical, Inc. San Clemente, CA USA.
11. Caruana RJ, et al. Thrombotic Complications of Indwelling Central Catheters Used for Chronic Hemodialysis. *Am J Kidney Dis* 1987; 9. 497-501.
12. Twardowski ZJ, Van Stone JC, Jones ME, et al. Blood Recirculation in Intravenous Catheters for Hemodialysis. *J Am Soc Nephrol* 1993; 4, 1978-1981.
13. McGee DC, Gould MK. Preventing Complications of Central Venous Catheterization: *N Engl J Med* 2003; 348: 1123-33.
14. Twardowski J. High-Dose Intradialytic Urokinase to Restore the Patency of Permanent Central Vein Hemodialysis Catheters. *Am J Kidney Dis* 1998; 31: 841-847.
15. Sitges-Serra A, Puig P, Linares J et al. Hub colonization as the initial step in an outbreak of catheter related sepsis due to coagulase negative staphylococci during parenteral nutrition. *JPEN* 8:668-672,1984.
16. Lenhart C. Prevention vs. Treatment of VAD Occlusions. *Journal of Vascular Access Devices*. Winter, 2000.
17. Gabriel J. Prevention and Management of Intraluminal Occlusion, 4th International IV Conference, Oxford, UK, March, 2004.
18. Test Report: Microbial Challenge and Disinfection Study for Tego Connector. March 3, 2004. Study on File; ICU Medical, Inc. San Clemente, CA USA.

ICU Medical is the world leader in needlefree intravenous connection devices. Our landmark technologies seek to improve patient outcomes while eliminating the risk of needle stick injuries in health care workers.

I

San Clemente, CA 92673 USA

www.icumed.com

949.366.2183 800.824.7890

US Patent Number: 6,695,817; Other US and Foreign Patents Pending M1-1148 Aug-04